Search

Gunjan Aggarwal - Criminal Judgment and Sentencing

U.S. District Court for the Northern District of California entered judgment in criminal case 4:23-cr-00428 against Gunjan Aggarwal. The defendant was sentenced to 18 months in federal prison followed by 2 years supervised release, with a $100 special assessment. A writ of garnishment was issued to collect restitution.

Nebraska Joins FTC and Coalition States Lawsuit Against Ad Agencies for Digital Advertising Collusion

Nebraska Attorney General Hilgers joined the FTC and eight states in filing an antitrust lawsuit against major advertising agencies WPP, Publicis, Dentsu, Omnicom, and IPG for allegedly colluding since 2018 to establish common 'Brand Safety Floor' standards targeting 'misinformation.' The complaint alleges that firms NewsGuard and the Global Disinformation Index were used to promote demonetization of disfavored political viewpoints, displacing competition in the market for ad-buying services. The ad agencies have agreed to a proposed consent order that would prevent engaging in agreements setting common brand safety standards or restricting advertising based on biased criteria. The complaint and order were filed in the U.S. District Court for the Northern District of Texas.

IPG11406 Phase 2 UC Trial, 144 Patients, 12 Weeks

NIH has registered a Phase 2 clinical trial (NCT07535489) for IPG11406, an investigational oral drug targeting the GPR183 receptor for ulcerative colitis. The randomized, double-blind, placebo-controlled study will enroll 144 adult patients across three active dose groups (10 mg, 20 mg, 40 mg twice daily) and one placebo arm over 12 weeks. The primary endpoint is clinical remission measured by modified Mayo Score at week 12, with secondary endpoints including clinical response, endoscopic remission, histological improvement, and safety evaluation.

6-Thio-dG Treatment for Pediatric Brain Tumors

The USPTO granted Patent US12594293B2 to The Board of Regents of The University of Texas System on April 7, 2026, covering the use of 6-thio-dG (a telomerase substrate precursor analog) to treat therapy-resistant telomerase-positive pediatric brain tumors including diffuse intrinsic pontine glioma (DIPG), high-grade glioma (HGG), and high-risk medulloblastoma. Inventors Jerry Shay and Rachid Drissi developed methods demonstrating that 6-thio-dG induces telomere dysfunction-induced foci, genomic DNA damage, cell death, and tumor growth delay in xenograft models.